Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y<sub>12</sub> inhibitor: A single ascending dose study in healthy humans
Fumitoshi Asai(Azabu University), Kenneth J. Winters(Eli Lilly (United States)), Takashi Hirota, John T. Brandt(Universitätsklinikum Würzburg), Stephen Freestone, Nobuko Matsushima, Joseph A. Jakubowski(Indiana Biosciences Research Institute), Hideo Naganuma(Daiichi-Sankyo (Japan))
Cited by 108
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617